Sculptor Capital LP Makes New Investment in Cogent Biosciences, Inc. $COGT

Sculptor Capital LP acquired a new position in Cogent Biosciences, Inc. (NASDAQ:COGT) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 50,000 shares of the technology company’s stock, valued at approximately $1,935,000.

Other large investors have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its stake in shares of Cogent Biosciences by 1,164.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company’s stock valued at $25,000 after acquiring an additional 652 shares during the period. J.Safra Asset Management Corp bought a new stake in Cogent Biosciences during the 2nd quarter worth approximately $27,000. Osaic Holdings Inc. raised its stake in Cogent Biosciences by 41.4% during the 2nd quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock worth $33,000 after acquiring an additional 1,333 shares during the period. Strs Ohio bought a new stake in Cogent Biosciences during the 1st quarter worth approximately $36,000. Finally, Global Retirement Partners LLC purchased a new position in Cogent Biosciences during the fourth quarter valued at approximately $37,000.

Cogent Biosciences Price Performance

COGT stock opened at $36.80 on Wednesday. Cogent Biosciences, Inc. has a 52 week low of $11.60 and a 52 week high of $43.73. The firm has a market capitalization of $6.39 billion, a P/E ratio of -17.04 and a beta of 0.38. The company has a fifty day simple moving average of $38.62 and a two-hundred day simple moving average of $36.61. The company has a quick ratio of 13.57, a current ratio of 13.57 and a debt-to-equity ratio of 0.48.

Cogent Biosciences (NASDAQ:COGT) last posted its earnings results on Monday, August 10th. The technology company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. Analysts anticipate that Cogent Biosciences, Inc. will post -2.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on COGT. HC Wainwright upped their price target on shares of Cogent Biosciences to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Wedbush restated an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a research report on Friday, May 29th. Piper Sandler lifted their target price on shares of Cogent Biosciences from $52.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Guggenheim lifted their target price on shares of Cogent Biosciences from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a report on Wednesday, July 8th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $49.40.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.